Professional paper - Letter to the editor
Second primary malignancies in myeloproliferative neoplasms and the role of aspirin
Leukemia, 33 (2019), 10; 2554. https://doi.org/10.1038/s41375-019-0553-2


Cite this document

Lucijanić, M., Skelin, M. & Kušec, R. (2019). Second primary malignancies in myeloproliferative neoplasms and the role of aspirin. Leukemia, 33. (10), 2554. doi: 10.1038/s41375-019-0553-2

Lucijanić, Marko, et al. "Second primary malignancies in myeloproliferative neoplasms and the role of aspirin." Leukemia, vol. 33, no. 10, 2019, p. 2554. https://doi.org/10.1038/s41375-019-0553-2

Lucijanić, Marko, Marko Skelin and Rajko Kušec. "Second primary malignancies in myeloproliferative neoplasms and the role of aspirin." Leukemia 33, no. 10 (2019): 2554. https://doi.org/10.1038/s41375-019-0553-2

Lucijanić, M., Skelin, M. and Kušec, R. (2019) 'Second primary malignancies in myeloproliferative neoplasms and the role of aspirin', Leukemia, 33(10), p. 2554. doi: 10.1038/s41375-019-0553-2

Lucijanić M, Skelin M, Kušec R. Second primary malignancies in myeloproliferative neoplasms and the role of aspirin. Leukemia [Internet]. 2019 August 21 [cited 2024 February 29];33(10):2554. doi: 10.1038/s41375-019-0553-2

M. Lucijanić, M. Skelin and R. Kušec, "Second primary malignancies in myeloproliferative neoplasms and the role of aspirin", Leukemia, vol. 33, no. 10, p. 2554, August 2019. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:646020. [Accessed: 29 February 2024]

Please login to the repository to save this object to your list.